Abstract
Alpha-fetoprotein (AFP) was first described in the human fetus in 1956 and became a marker protein of primary liver cancer in adults. Serum AFP levels were measured by radioimmunoassay in 212 patients with a variety of malignant and nonmalignant diseases to determine the incidence of leveis elevated above 40 ng/ml. The results obtained are as follows: In 44 cases of total 212 patients, abnormal AFP levels above 40 ng/ml in serum were measured; 24 of 31 patients with primary hepatocellular carcinoma and primary hepatocellular carcinoma with liver cirrhosis (77.4%), 7 of 51 patients with only liver cirrhosis (13.7%), 4 of 10 patients with metastatic liver cancer (40.0%), 4 of 15 patients with chronic hepatitis (26.7%), 2 of 23 patients with acute hepatitis (8.7%), and each one patient with 6 pancreatic carcinoma and 9 cholangiocarcinoma had elevated serum AFP levels. One pregnant woman with gestation 35 weeks had elevated level, but within normal limit during pregnancy.
Kim, Y H;
Choi, K A;
Ahn, K S;
Suh, W H;
Lee, M J
[1]
- Korea University College of Medicine, Seoul (Korea, Republic of)
Citation Formats
Kim, Y H, Choi, K A, Ahn, K S, Suh, W H, and Lee, M J.
The radioimmunoassay of serum alpha-fetoprotein levels.
Korea, Republic of: N. p.,
1982.
Web.
Kim, Y H, Choi, K A, Ahn, K S, Suh, W H, & Lee, M J.
The radioimmunoassay of serum alpha-fetoprotein levels.
Korea, Republic of.
Kim, Y H, Choi, K A, Ahn, K S, Suh, W H, and Lee, M J.
1982.
"The radioimmunoassay of serum alpha-fetoprotein levels."
Korea, Republic of.
@misc{etde_21211850,
title = {The radioimmunoassay of serum alpha-fetoprotein levels}
author = {Kim, Y H, Choi, K A, Ahn, K S, Suh, W H, and Lee, M J}
abstractNote = {Alpha-fetoprotein (AFP) was first described in the human fetus in 1956 and became a marker protein of primary liver cancer in adults. Serum AFP levels were measured by radioimmunoassay in 212 patients with a variety of malignant and nonmalignant diseases to determine the incidence of leveis elevated above 40 ng/ml. The results obtained are as follows: In 44 cases of total 212 patients, abnormal AFP levels above 40 ng/ml in serum were measured; 24 of 31 patients with primary hepatocellular carcinoma and primary hepatocellular carcinoma with liver cirrhosis (77.4%), 7 of 51 patients with only liver cirrhosis (13.7%), 4 of 10 patients with metastatic liver cancer (40.0%), 4 of 15 patients with chronic hepatitis (26.7%), 2 of 23 patients with acute hepatitis (8.7%), and each one patient with 6 pancreatic carcinoma and 9 cholangiocarcinoma had elevated serum AFP levels. One pregnant woman with gestation 35 weeks had elevated level, but within normal limit during pregnancy.}
journal = []
issue = {2}
volume = {18}
place = {Korea, Republic of}
year = {1982}
month = {Jun}
}
title = {The radioimmunoassay of serum alpha-fetoprotein levels}
author = {Kim, Y H, Choi, K A, Ahn, K S, Suh, W H, and Lee, M J}
abstractNote = {Alpha-fetoprotein (AFP) was first described in the human fetus in 1956 and became a marker protein of primary liver cancer in adults. Serum AFP levels were measured by radioimmunoassay in 212 patients with a variety of malignant and nonmalignant diseases to determine the incidence of leveis elevated above 40 ng/ml. The results obtained are as follows: In 44 cases of total 212 patients, abnormal AFP levels above 40 ng/ml in serum were measured; 24 of 31 patients with primary hepatocellular carcinoma and primary hepatocellular carcinoma with liver cirrhosis (77.4%), 7 of 51 patients with only liver cirrhosis (13.7%), 4 of 10 patients with metastatic liver cancer (40.0%), 4 of 15 patients with chronic hepatitis (26.7%), 2 of 23 patients with acute hepatitis (8.7%), and each one patient with 6 pancreatic carcinoma and 9 cholangiocarcinoma had elevated serum AFP levels. One pregnant woman with gestation 35 weeks had elevated level, but within normal limit during pregnancy.}
journal = []
issue = {2}
volume = {18}
place = {Korea, Republic of}
year = {1982}
month = {Jun}
}